|
Market Report
|
Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
|
|
Read more...
|
|
|
Market Report
|
Monoclonal Antibodies Report Market Model
The model provides a comprehensive analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
|
|
Read more...
|
|
|
Market Report
|
Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.
|
|
Read more...
|
|
|
Market Report
|
 Primary Brain Cancer
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.
|
|
Read more...
|
|
|
Market Report
|
Asthma & COPD - Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
|
|
Read more...
|
|
|
Market Report
|
HIV - Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.
|
|
Read more...
|
|
|
Market Report
|
Upper GI Disorders - Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
|
|
Read more...
|
|
|
Market Report
|
The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
|
|
Read more...
|
|
|
Market Report
|
New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 82 - 90 of 238 |
Farmavita.Net Journal 
